2-(Chloromethyl)oxirane;prop-2-en-1-amine;hydrochloride

Base Information

• Chemical Name: 2-(Chloromethyl)oxirane;prop-2-en-1-amine;hydrochloride
• CAS No.: 152751-57-0
• Molecular Formula: (C3H7N)m^.(C3H5ClO)n^.(HCl)x
• Molecular Weight: 149.61900
• European Community (EC) Number: 682-522-4
• NCI Thesaurus Code: C66538
• RXCUI: 237125
• Mol file: 152751-57-0.mol

Synonyms:Carbonate, Sevelamer;GT335 012;GT335-012;GT335012;Hydrochloride, Sevelamer;RenaGel;sevelamer;sevelamer carbonate;sevelamer hydrochloride

Chemical Property of 2-(Chloromethyl)oxirane;prop-2-en-1-amine;hydrochloride

Chemical Property:

• Vapor Pressure: 22mmHg at 25°C
• Boiling Point: 116.1oC at 760 mmHg
• Flash Point: 33.9oC
• PSA: 38.55000
• LogP: 1.45540
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 2
• Exact Mass: 185.0374194
• Heavy Atom Count: 10
• Complexity: 55.1

Purity/Quality:

99% ^*data from raw suppliers

SevelamerHydrochloride(TechnicalGrade) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C=CCN.C1C(O1)CCl.Cl
• Recent ClinicalTrials: Different Effects of Non-calcium Phosphate Binders on Serum Calcium
• Recent EU Clinical Trials: An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.
• Recent NIPH Clinical Trials: Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized controlled analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis
• Uses: Sevelamer hydrochloride is a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure or patients suffering from chronic kidney disease. Sevelamer hydrochloride is a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Sevelamer HCl is used in the treatment of hyperphosphataemia in patients suffering from chronic kidney disease.
• Therapeutic Function: Antihyperphosphatemic